The Street is in love with the platform, and not without reason. Moderna's annual report describes three commercial respiratory vaccines and a pipeline built on the idea that one mRNA technology can be pointed at many diseases. That is the steelman, and it is a serious one. But read the risk factors — and the XBRL — and a harder number sits underneath the story.

The cliff is closer than the deck admits. Per the structured data in its FY2025 10-K, filed February 20, 2026, Moderna's research-and-development expense was $4.8 billion in 2023, $4.5 billion in 2024, and $3.1 billion in 2025. Over the same window, year-end cash and cash equivalents went $2.9 billion (2023), $1.9 billion (2024), $2.6 billion (2025). For a stretch there, the company was spending more on R&D in a single year than it held in cash at year-end.

Strip away the platform romance and that is what a post-blockbuster re-rating looks like in the accounts: revenue that surged during the pandemic, then a spending base that had been sized for a much larger company. The cut from $4.8 billion to $3.1 billion in R&D is not a footnote — it is roughly a 35% reduction, and it is the company adjusting its cost structure to its new revenue reality.

Acknowledge the bull case before dismantling it: cash and equivalents are not the whole liquidity picture. Moderna also holds investments beyond the narrow cash line, and a quarterly figure can swing on timing. The first-quarter 2026 10-Q tagged quarterly R&D of $649 million, down from $856 million a year earlier — confirming the discipline is continuing, not a one-off. So the bears who scream they're going broke are overreaching. The point is narrower and harder to dodge.

The narrow point: the company that built the most celebrated mRNA platform in the world is now being run as a cash-conservation exercise, and the filings prove it. R&D is falling because it has to, not because the science ran out of ideas. The EdgarBeast evidence index lets anyone pull these exact tags across years and watch the spending base shrink toward the cash base.

So when someone tells you Moderna is a platform story, agree — and then ask the platform a question the filing already answers: at what spend, against what cash, for how long? The science may be broad. The runway is the constraint, and it is disclosed, not hidden.